Original from: business wire
Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of the DISQVER® clinical metagenomics platform from Noscendo GmbH.
DISQVER® enables metagenomic next-generation sequencing (mNGS) analysis of microbes directly from blood samples, further expanding Bruker's NGS-based infection detection capabilities. Without any need for prior cultivation, DISQVER analyzes whole genome sequencing (WGS) data and applies advanced, proprietary bioinformatics to search for more than 11,000 different microbes and parasites. The mNGS analysis can be done directly from cell-free DNA samples from blood, in less than 24 hours after sample receipt. This advanced mNGS clinical research approach can be valuable for bloodstream infections, sepsis, endocarditis, and other severe infectious diseases.
Following the acquisition, DISQVER® remains available for research use only, while Bruker is progressing its registration for diagnostic purposes. Financial details of the transaction were not disclosed, and DISQVER® is not expected to be material to Bruker’s FY26 financial results.
Dr. Wolfgang Pusch, President of Bruker Microbiology & Infection Diagnostics, commented: “The acquisition of the DISQVER® proprietary software and workflow platform is the latest step in our evolution as an innovative microbiology and molecular diagnostics business. We have expanded into rapid antimicrobial susceptibility testing (AST), hospital hygiene testing, sample-to-answer molecular diagnostics with the ELITech Genius platform, and most recently into NGS for infectious disease testing. DISQVER® adds additional NGS applications to our portfolio for metagenomics, and enhances our support for earlier decision-making in sepsis, bloodstream infections, and severe infections."
Source: Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER® Platform for Pathogenic Microorganisms in Blood
